Nasal delivery is an emerging strategy to prevent both local and systemic diseases. The aim of this study was to develop a promising and innovative therapeutic system for the nasal delivery system of liposomes. Ovalbumin (OVA) was used as a model compound in this study. For this purpose we have developed OVA containing gel formulations using chitosan(2% w/v) and Carbopol (R) 974P(0.25% w/v). The developed gels have appropriate pH and viscosity for mucosal administration. We have also developed OVA containing liposome formulation for nasal administration. The developed liposomes have negative zeta potential(-5.33 mV +/- 2.019), 200-250 nm particle size and 73% entrapment efficiency. To improve the mucosal retention time, liposome was dispersed in chitosan gel(lipogel). It was shown that developed formulations do not show cell toxicity, by cell viability near 100% on Calu-3 cells which is a model cell line of the respiratory mucosa. Sodium dodecyl sulfate polyacrylamide gel electrophoresis(SDS-PAGE) results of the formulations also showed that the antigen OVA maintained its integrity except liposome in chitosan gel formulation. We have also evaluated mucoadhesive and mechanical properties of the formulations on sheep nasal mucosa. Results from this study indicate that carbopol gel and lipogel formulations may be effective as nasal delivery systems.